132 results about "Vascular complication" patented technology

Diagnostic dry reagent tests capable of reacting with a single drop of whole blood and reporting both glucose and light-scattering analytes, such as chylomicrons, are taught. Such dry reagent tests may employ electrochemical detection methodologies, optical detection methodologies, or both methodologies. These tests alert diabetics to excessive levels of postprandial lipemia caused by meals with excessive amounts of fat, and thus can help reduce the risk of cardiovascular complications in diabetic patients.

Methods for determining a potential of a hyperglycemic patient to develop vascular complications in response to oxidative stress and for determining the importance of reducing oxidative stress in a specific hyperglycemic patient are disclosed. Each method includes the step of determining a haptoglobin phenotype of the patient. A variety of means of making this determination are further disclosed.

The present invention relates to a method and means for diagnosing or risk stratification of co-morbidities, particularly cardiovascular complications in diabetes patients. The invention particularly relates to a method for diagnosing whether a diabetes patient is suffering from a cardiovascular complication or is at risk of suffering from a cardiovascular complication, said method comprising the steps of (a) measuring, preferably in vitro, the level(s) of at least one cardiac hormone or a variant thereof in a sample from the patient, and (b) diagnosing the cardiovascular complication or the risk of suffering from cardiovascular complication by comparing the measured level(s) to known level(s) associated with the cardiovascular complication or risk. The present invention also relates to combining the measurement of markers comprising cardiac hormones, natriuretic peptides, inflammation-associated markers, angiogenesis markers, and markers for platelet activation. Preferred markers are brain natriuretic peptides (particularly NT-proBNP), PIGF, and sCD40L.

The present invention relates generally to the field of hemostasis, including methods, compositions, and devices that can be employed to achieve hemostasis at an increased rate. More specifically the present invention relates to hemostatic compositions that achieve a hemostatic effect at a distance from the site of application of the composition, and a method for administering such a composition to effectively reduce localized vascular complications associated with treating a breach or puncture in a vein or artery and reduce the time to achieve hemostasis.

The present invention relates generally to the field of hemostasis, including methods, compositions, and devices that can be employed to achieve hemostasis at an increased rate. More specifically the present invention relates to hemostatic compositions that achieve a hemostatic effect at a distance from the site of application of the composition, and a method for administering such a composition to effectively reduce localized vascular complications associated with treating a breach or puncture in a vein or artery and reduce the time to achieve hemostasis.

Methods whereby, by reference to fructosamine oxidase activity in blood plasma of a patient or patients, the risk of diabetes associated vascular complications can be assessed, candidate fructosamine oxidase inhibitors and / or antagonists can be identified or tested and the inhibition and / or antagonism of the fructosamine oxidase inhibition and / or antagonism of a patient can be assessed.

The present invention is directed to a novel methods and compositions for the therapeutic intervention of vascular complications associated with diabetes, hyperlipidemias, and various cardiovascular disorders including but not limited to recalcitrant hypertension, coronary artery disease, pulmonary arterial hypertension, congestive heart failure, and hemolytic anemias. More specifically, the specification describes methods and compositions for treating such vascular disorders using compositions comprising BH4 and derivative thereof. Combination therapies of BH4 and other therapeutic regimens are contemplated.

The present invention relates to a method and means for diagnosing or risk stratification of co-morbidities, particularly cardiovascular complications in diabetes patients. The invention particularly relates to a method for diagnosing whether a diabetes patient is suffering from a cardiovascular complication or is at risk of suffering from a cardiovascular complication, said method comprising the steps of (a) measuring, preferably in vitro, the level(s) of at least one cardiac hormone or a variant thereof in a sample from the patient, and (b) diagnosing the cardiovascular complication or the risk of suffering from cardiovascular complication by comparing the measured level(s) to known level(s) associated with the cardiovascular complication or risk. The present invention also relates to combining the measurement of markers comprising cardiac hormones, natriuretic peptides, inflammation-associated markers, angiogenesis markers, and markers for platelet activation. Preferred markers are brain natriuretic peptides (particularly NT-proBNP), PIGF, and sCD40L.

The invention relates to a drug for reducing blood glucose, regulating blood lipid and treating diabetes mellitus combined with hyperlipidemia and other chronic vascular complications and a preparation method thereof. The drug is total alkaloids which are extracted from traditional Chinese medicine golden thread. The preparation method of the drug comprises the following steps: 1) the golden thread herbal medicine is crushed into coarse powder; 2) 5-10 times of the amount of 60-80 percent ethanol is used for carrying out the reflux extraction of the golden thread coarse powder for 1-3 times by 1-2h / time, the filtration is carried out by times, and filtrates are merged. Golden thread extract is obtained by pressure reduction concentration and drying; 3) the golden thread extract is added in 5 times of the amount of 0.5 percent sulfuric acid for dissolution and filtration, the filtrates are respectively regulated to pH9 by lime milk, filtrated and respectively regulated to pH1-2 by hydrochloric acid, sodium chloride is added to allow the salt content to be 10 percent, and the total alkaloids of the golden thread are obtained by even shaking and still placement. Or the golden thread extract is used for separating and purifying the total alkaloids of the golden thread by macroporous resin method. The drying is carried out, and the total alkaloids of the golden thread are prepared into oral formulation or injection formulation. The drug has prominent efficacy for the diabetes mellitus combined with hyperlipidemia and other chronic vascular complications.

A method of evaluating a risk of a subject to develop vascular complications is disclosed. The method is effected by determining a haptoglobin phenotype of the subject and thereby evaluating the risk of the subject to develop vascular complications. The risk is decreased in patients with haptoglobin 1-1 phenotype as compared to patients with haptoglobin 1-2 or haptoglobin 2-2 phenotypes.

The invention discloses novel crystal form III and crystal form IV of 1-(beta-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl, a preparation method of the crystal form III and the crystal form IV and a medicinal application of the crystal form III and the crystal form IV in treatment of diabetes mellitus. The crystal form III serving as an octanol compound has a more remarkable action effect on treatment of diabetes mellitus, and is prepared by carrying out supersaturated precipitation or re-crystallization in octanol or a solution containing octanol. The octanol serving as a gap junction blocker has an effect of reducing diabetic complications, such as a pharmacological action for resisting cardiomyocyte edema and hypertrophy and a neuroprotective effect, so that compared with other crystal forms, the crystal form III has a more remarkable action effect on diabetes mellitus treatment, especially prevention of cardiovascular complications of patients with early diabetes mellitus.

The present invention provides methods for the prevention or treatment of one or more vascular complication(s) in a subject at risk of developing diabetes mellitus, impaired glucose tolerance and / or hyperglycemia or a subject suffering from diabetes mellitus, impaired glucose tolerance and / or hyperglycemia, wherein an amount of a composition effective to inhibit, repress, delay or otherwise reduce expression and / or activity and / or level of TXNIP and / or an amount of a composition effective to induce, enhance or otherwise increase expression and / or activity and / or level of TRX is / are administered to a subject in need thereof. The present invention also provides methods for identifying and isolating modulators of TXNIP expression and / or activity and / or level and / or TRX expression and / or activity and / or level for use in such therapeutic and prophylactic methods.

The invention relates to a radial artery dual-airbag intelligent compression hemostasis device which comprises a wristband, a radial artery airbag, an ulnar artery airbag, an oxyhemoglobin saturation monitoring probe, a pressure sensor, a program control air pump, a program control switch and a control terminal. The radial artery airbag and the ulnar artery airbag are arranged on the wristband in a spaced mode and connected with the program control air pump. Connecting pipe fittings of the airbags and the program control air pump are provided with an air outlet and a pressure sensor. The program control switch is arranged at the air outlet. The control terminal comprises a single-chip microcomputer, a man-machine interaction operation button and a displayer. The radial artery oxyhemoglobin saturation monitoring result can be converted into signals of waveform, oxyhemoglobin saturation value and sound intensity of pulse waves, the single-chip microcomputer determines the pressure exerted on a patient radial artery according to the signals, the inflation pressure in the airbags is fed back and adjusted through the program control air pump and the program control switch, and the blood vessel complications and damage which are caused to a patient when the pressure in the airbags is too high or too low and the pressing time is too long or too short are avoided.

The present invention relates to a method for treating one or more diabetic microvascular complications in a patient in need of said treatment comprising: (a) diagnosing the severity of at least three different microvascular complications in said patient by calculating a diabetes microvascular complications score with a diabetes microvascular complications scoring tool; and (b) administering to said patient in need thereof a therapeutic amount of a compound selected from the group consisting of ruboxistaurin, enzastaurin, PKC 412, candesartan cilexetil, fidarestat, lidorestat, pyridoxamine and pegaptanib, or a pharmaceutically acceptable salt thereof, and ranibizumab; in an amount that is effective in treating one or more diabetic microvascular complications in said diabetic patient.

The invention relates to a compound dendrobium candidum hypoglycemic composition and a preparation method thereof. The compound dendrobium candidum hypoglycemic composition is prepared from the following Chinese traditional medicine raw materials in weight ratio: 2-40g of dendrobium candidum, 5-80g of prepared rehmannia root, 5-80g of Chinese wolfberry, 5-80g of dogwood, 5-80g of dodder, 5-80g of milk vetch, 5-80g of wolfberry bark, 2-40g of coptis, 5-80g of rhizoma atractylodis, 5-80g of gallnut, 5-80g of root-bark of tree peony and 2-40g of licorice. The compound dendrobium candidum hypoglycemic composition provided by the invention can improve the immunity of the human body, regulate the equilibrium between yin and yang of the human body, obviously reduce the blood sugar level, obviously improve the symptoms of diabetes, enhance the memory, nourish the consumptive disease of the five internal organs, resist the aging, inhibit the tumor and resist the anoxia, has an obvious effect on diabetes with deficiency of both qi and yin and blood stasis syndrome and vascular complications thereof, is suitable for treating diabetes complicated with coronary heart disease, cerebral vascular diseases, peripheral vascular diseases, retinopathy, diabetic nephropathy and the like, and does not have toxic or side effects.

The invention relates to the fields of pharmaceutical chemistry and particularly provides a series of nitric oxide-donating chrysin derivatives, which are prepared by modifying the chrysin at position 5 and position 7. The nitric oxide-donating chrysin derivatives release nitric oxide and chrysin derivatives in vivo and therefore can conduct functions of reducing blood sugar and blood pressure, promoting angiogenesis, improving a vascular endothelial function and lipid metabolism disorders and can be used in the preparation of medicaments for treating diabetes, diabetic cardiovascular complications, metabolic syndrome and endothelial dysfunction.

The invention discloses a heart auxiliary device which comprises an outer shell. The outer shell is formed by bonding and fixing a non-elastic flexible rope on the outer surface of a heart model in a spiral mode, a sealed left air bag is arranged along the outer surface of a left heart chamber of the heart model and located in the outer shell, a sealed right air bag is arranged along the outer surface of a right heart chamber of the heart model and located in the outer shell, buckling rings are arranged on the upper portions of the inner walls, close to the side wall of the left air bag and the side wall of the right air bag, of the outer shell respectively, the upper end of the left air bag and the upper end of the right air bag are fixed on the buckling rings, a lower opening of the left air bag is communicated with a left air inlet pipe, a lower opening of the right air bag is communicated with a right air inlet pipe, the left air inlet pipe and the right air inlet pipe penetrate out of the heart apex at the bottom of the outer shell and extend outwards, and the extending parts of the left air inlet pipe and the right air inlet pipe are communicated with an air source control device. The heart auxiliary device is not in direct contact with blood, anticoagulation is not needed in the application process, a series of blood vessel complications like bleeding, thrombosis, hemolysis and immunoreactions are avoided, the infection rate is reduced, and the heart auxiliary device can be suitable for single-heart-chamber assistance and double-heart-chamber assistance, and is flexible in using method.

A method of determining a potential of a diabetic patient to benefit from anti oxidant therapy for treatment of a vascular complication, the method comprising determining a haptoglobin phenotype of the diabetic patient and thereby determining the potential of the diabetic patient to benefit from said anti oxidant therapy, whereby a patient having a haptoglobin 2-2 phenotype benefits from anti oxidant therapy more than a patient having a haptoglobin 1-2 phenotype or a patient having a haptoglobin 1-1 phenotype.

A method of determining a potential of a nondiabetic or diabetic patient to benefit from reverse cholesterol transport therapy for treatment of a vascular complication, followed by methods and compositions of treating the diagnosed vascular complications comprising determining a haptoglobin phenotype of the patient. Reverse cholesterol transport therapy includes inhibition of cholesteryl ester transport protein, such as by using the compound torcetrapib.

A pharmaceutical composition that includes a carbamoyloxy arylalkanoyl arylpiperazine compound SERUM CHOLESTEROL and effectively prevents or treats diabetic nephropathy, diabetic neuropathy, diabetic vascular complications, hyperlipidemia, coronary artery disease, or inflammation.

The group of inventions is directed to improving the reliability and objectivity of assessment of the risk of cardiovascular complications. Using optical capillaroscopy of the nail fold of a finger in a state of reactive hyperemia and in the absence thereof, the size of the perivascular area and the diameters of the venous and arterial portions of the capillaries are measured. pulse wave velocity and the level of endothelial function in the upper limb are measured simultaneously relative to the R peak of an electrocardiogram, and an index K of the risk of cardiovascular complications is calculated using the given expression and categorized. The device comprises: a pneumatic means for creating occlusion in a limb of the patient and pressure sensors connected to occlusion cuffs; an input unit capable of receiving and regulating the level of signals from the output of the pressure sensors and of amplifying and pre-filtering said signals; an optical capillaroscopy unit capable of measuring the size of the perivascular zone and the diameters of the venous and arterial portions of the nail fold capillaries of a finger in a state of reactive hyperemia and in the absence thereof; an electrocardiogram recording unit capable of generating a pulsed synchronization signal based on the R wave of the electrocardiogram; a unit for amplitude-to-digital conversion, digital signal processing and control, a switching unit, and a unit for communicating with a computer.

The present invention relates to a method for differentiating in a subject suffering from acute shortness of breath (dyspnea) between (i) a pulmonary disease, (ii) a cardiovascular complication, (iii) a cardiovascular complication accompanied by a pulmonary disease or (iv) acute dyspnea without cardiovascular or pulmonary causes comprising the steps of determining the amount of pulmonary surfactant protein B (SP-B) in a sample of a subject, determining the amount of a natriuretic peptide in a sample of said subject, and differentiating between (i) a pulmonary disease, (ii) a cardiovascular complication, (iii) a cardiovascular complication accompanied by a pulmonary disease or (iv) acute dyspnea without cardiovascular or pulmonary causes by comparing the determined amounts with reference amounts. Moreover, the present invention relates to a device and a kit for carrying out said method.

The present embodiments relate to novel uses of MPO inhibitors and inhibitors of MPO and E-selectin binding. In some embodiments, methods are provided for treating G-CSF-induced vascular complications and associate tissue injury comprising administering to a subject in need thereof a compound that inhibits E-selectin receptor / ligand interaction or inhibits MPO activity. The inhibitors may be administered in conjunction with G-CSF therapy. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics (including aptamers) and organic compounds (e.g., glycomimetics).

A novel herbal formulation for the prevention and management of diabetes mellitus and its significance in the prevention of diabetic micro-vascular complications. A novel herbal formulation for the prevention of endothelial dysfunction Diabetes Mellitus and Diabetic Micro-Vascular complications comprising: Salacia chinensis and at least one other active constituent selected from Coccinia indica and Hippophae rhamnoides and optionally additives in trace amounts.

The present invention provides a method for treating diabetic vascular complications including administering to a subject in need thereof a therapeutically effective amount of an extract product of a Dioscorea species. The extract product preferably is prepared by a process which involves (a) extracting a tuber of the Dioscorea species with an alcohol-based solvent in the presence of an acetic acid solution to form an extract composition, (b) subjecting a resultant product obtained in step (a) to obtain a soluble fraction, and (c) removing solvent from the soluble fraction obtained in step (b) to obtain the extract product.

Disclosed herein are compositions and methods for the identification of a subject at risk for developing microvascular complications associated with diabetes such as diabetic nephropathy and diabetic retinopathy. Also disclosed is a therapeutic target for the prevention and treatment of microvascular complications associated with diabetes.

The invention belongs to the technical field of biology and diagnosis, and relates to a receptor of a definite, effective and visualized platelet reactivity biomarker P2Y12 and an application thereof for diagnosing and predicting the II-type diabetic vascular complication risk. The platelet activation biomarker P2Y12 can detect expression levels of platelet through fluorescent quantitative polymerase chain reaction (PCR), Western blot, enzyme linked immunosorbent assay (ELISA), flow cytometry, UV spectrophotometry-near infrared spectrometry, high performance liquid chromatography, colorimetry, a mass spectrum identification method and the like and detect content of P2Y12 in whole blood. The invention also provides a method of biomarker P2Y12 for diagnosing and predicting vascular complication of subjects as well as a medicine for treating II-type diabetic vascular complication and a screening method of the medicine. The invention further provides an intervene plane for individualizing P2Y12 inverse agonist and accurately treating the vascular complication of II-type diabetic patients.

The invention provides use of glucagon-like peptide-1 (GLP-1) for preparing medicines for preventing and treating macrovascular complications of type 2 diabetes. The experiments show that GLP-1 has the anti-apoptosis effect by inhibiting the JNK (Jun N-terminal Kinase) signal paths of aortic endothelial cells of mice, increasing expression of Bc1-2 and inhibiting the activity of caspase-3. The effect is probably completed by promoting ROS (Reactive Oxygen Species) in scavenger-cells to exert anti-oxidative damage effect. GLP-1 in vitro and in vivo can remarkably improve degree of injury of great vessels of mice with type 2 diabetes. Therefore, GLP-1 can be used for preparing medicines for preventing and treating macrovascular complications of type 2 diabetes. The invention further provides a pharmaceutical composition for preparing medicines for preventing and treating macrovascular complications of type 2 diabetes.